Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10379371 | 0.79 | SRD5A1 (0.37) | CYP11B1CYP11B2DDB1CRBNALDH1A1 | |
| SCHEMBL10688708 | 0.79 | LMNA (0.36) | KDM4EDDB1CRBNHSD17B10ALDH1A1 | |
| SCHEMBL10377999 | 0.79 | SRD5A1 (0.40) | CYP11B1CYP11B2DDB1CRBNPARP1 | |
| SCHEMBL10686542 | 0.79 | SRD5A1 (0.37) | DDB1CRBNALDH1A1PARP1LMNA | |
| SCHEMBL10685831 | 0.79 | CYP19A1 (0.35) | CYP11B1CYP11B2DDB1CRBNCYP19A1 | |
| SCHEMBL10923229 | 0.77 | CRBN (0.43) | CYP11B1CYP11B2CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL19629535 | 0.76 | KDM4E (0.42) | KDM4EHSD17B10ALDH1A1PARP1PRKCI | |
| SCHEMBL10689321 | 0.76 | ABL1 (0.39) | CYP11B1CYP11B2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL10689555 | 0.75 | CYP1A2 (0.36) | CYP11B1CYP11B2DDB1CRBNCYP1A2 | |
| SCHEMBL10377744 | 0.72 | KDM4E (0.39) | CYP2D6CYP2C19KDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0197318-B1 | Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-05-09 | — | — | EP | claimed |
| US-4742061-A | Benzoc[c]-1,5-naphthyridines and related compounds as memory enhancing agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | claimed |
| US-4652567-A | Benzo(c)-1,5-naphthyridines useful for treating a patient having drug induced memory impairment in need of memory enhancement | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-03-24 | — | — | US | claimed |
| EP-0197318-A1 | Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-10-15 | — | — | EP | claimed |
| US-20020160984-A1 | Fused tricyclic compounds, methods and compositions for inhibiting parp activity | GUILFORD PHARMACEUTICALS INC. | 2002-10-31 | — | — | US | disclosed |
| US-6380193-B1 | POLY(ADENOSINE 5'-DIPHOSPHO-RIBOSE)POLYMERASE; TREATMENT OR PREVENTION OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES, VASCULAR STROKE | GUILFORD PHARMACEUTICALS INC. | 2002-04-30 | — | — | US | disclosed |
| US-6121278-A | POLY(ADENOSINE 5'-DIPHOSPHO-RIBOSE)POLYMERASE (PARP) ENZYME INHIBITOR FOR TREATMENT OF NEUROLOGICAL DISORDERS, ARTHRITIS, DIABETES, INFLAMMATION, CARDIOVASCULAR DISORDERS, SEPTIC SHOCK, CANCER | GUILFORD PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999011644-A1 | DI-N-HETEROCYCLIC COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| EP-0197318-B1 | Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-05-09 | — | — | EP | disclosed |
| US-4742171-A | AROMATIZATION, REARRANGEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4742171-A | AROMATIZATION, REARRANGEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4742171-A | AROMATIZATION, REARRANGEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4742061-A | Benzoc[c]-1,5-naphthyridines and related compounds as memory enhancing agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4670562-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4652567-A | Benzo(c)-1,5-naphthyridines useful for treating a patient having drug induced memory impairment in need of memory enhancement | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0197318-A1 | Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160984-A1 | Fused tricyclic compounds, methods and compositions for inhibiting parp activity | PARP4, PARP1, PARP6 | CYP11B1 681/4885CYP11B2 692/4885CYP2D6 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.